Welcome to our dedicated page for Kyowa Hakko news (Ticker: KYKOY), a resource for investors and traders seeking the latest updates and insights on Kyowa Hakko stock.
News for KYOWA HAKKO KOGY UNSP/ADR (KYKOY) centers on announcements from Kyowa Kirin Co., Ltd., a Japan-based global specialty pharmaceutical company. Recent releases highlight clinical trial milestones, scientific presentations, strategic collaborations and portfolio decisions across the company’s focus areas in immunology, hematology-oncology, bone and mineral disorders, and rare diseases.
A major theme in Kyowa Kirin’s news flow is the development of rocatinlimab, an investigational anti-OX40 human monoclonal antibody described as a potential T-cell rebalancing therapy for moderate to severe atopic dermatitis. Updates include top-line results from Phase 3 ROCKET trials such as HORIZON, IGNITE and the long-term ASCEND extension, as well as planned presentations at major dermatology congresses. These articles detail efficacy endpoints like EASI-75 and Investigator Global Assessment scores, safety findings and long-term maintenance data.
Another recurring topic is Kyowa Kirin’s work in hematology and hemato-oncology. News includes a global strategic collaboration with Kura Oncology to develop and commercialize ziftomenib, a selective oral menin inhibitor in development for acute myeloid leukemia and other hematologic malignancies. Releases describe how responsibilities are shared between the companies in the United States and other regions.
Kyowa Kirin also reports extensively on X-linked hypophosphatemia (XLH), sharing real-world evidence from the XLH Disease Monitoring Program and new analyses of disease burden, work productivity and treatment outcomes. Additional items cover presentations on burosumab (CRYSVITA) and XLH at scientific meetings, as well as updates on a long-standing research alliance with La Jolla Institute for Immunology and the decision to end distribution of Fareston (toremifene) tablets in the United States.
Investors and observers can use this news stream to follow Kyowa Kirin’s disclosed clinical progress, research partnerships and portfolio focus as they relate to the KYKOY ADR.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kyowa Kirin has appointed Steve Schaefer as the new President of North America, effective April 11, 2023. Schaefer joins from Takeda where he held senior roles, including Senior Vice President of the Neuroscience Business Unit. With over 25 years of experience in the pharmaceutical sector, he has been integral in managing multi-billion dollar commercial portfolios and is known for his expertise in advanced analytics and sales operations.
Schaefer succeeds Gary Zieziula, who is retiring after leading the company through significant growth since April 2020. Under Zieziula's leadership, Kyowa Kirin North America has become the fastest-growing region for the company, contributing over a quarter of global revenues. The transition aims to further enhance Kyowa Kirin's innovative therapies across North America.
Kyowa Kirin Co., Ltd. announces the presentation of Phase 2b study data for rocatinlimab (KHK4083/AMG 451) at the American Academy of Dermatology 2023 Annual Meeting from March 17-22 in New Orleans. The trial involved 274 patients with moderate-to-severe atopic dermatitis, demonstrating significant reductions in serum IgE concentrations and improvements in patient-reported outcomes. Rocatinlimab's IgE reductions were maintained to Week 56. The study's adverse events were similar across groups, with no serious complications reported. Collaborative efforts with Amgen are also highlighted to further develop this potential treatment.
Kyowa Kirin Co., Ltd. announced the presentation of data from its Phase 2b study of rocatinlimab at the American Academy of Dermatology 2023 Annual Meeting on March 17-21 in New Orleans. Rocatinlimab, an investigational anti-OX40 monoclonal antibody, aims to treat moderate-to-severe atopic dermatitis, which affects approximately 15-20% of children and 10% of adults globally. Two posters will be presented, focusing on its efficacy and the reduction of IgE concentrations. Kyowa Kirin has partnered with Amgen for the development and commercialization of rocatinlimab globally, except in Japan, where it retains rights.